Sydney, June 9, 2026, 19:10 AEST
CSL Ltd shares rose on Tuesday, standing out in a softer Australian market, as healthcare buying helped the biotech close 1.59% higher at A$99.47. ResMed gained 1.30% and Ramsay Health Care added 2.79%, putting CSL’s move in a wider defensive-healthcare bid rather than an isolated stock bounce.
The broader market did not follow. The S&P/ASX 200 lost 0.24% at the Sydney close, with losses in gold, metals and mining, and materials dragging the index lower; falling stocks outnumbered risers by almost two to one.
The timing mattered. Tuesday was the first regular session after the ASX cash market was shut on Monday for the King’s Birthday holiday, leaving investors to reset positions after a long weekend and a bruising period for global risk appetite.
CSL remains a stock with baggage. The share price is still below A$100, a level it fell through in May after the company flagged about US$5 billion in additional non-cash impairments and weaker revenue assumptions, sending the shares down more than 20% at the time.
There was no fresh operating update behind Tuesday’s move. CSL’s announcements page listed a June 9 “Notification of cessation of securities” after director and substantial-holder notices earlier this month; the last major financial update on the page remains the May 11 interim CEO review. CSL Limited
CSL reports in U.S. dollars, while its ASX shares trade in Australian dollars, so the A$99.47 close is a market price and not the currency used in its earnings guidance. The company’s annual report says the group’s presentation currency, and the parent entity’s functional currency, is U.S. dollars.
In the May update, CSL guided to FY26 revenue of about US$15.2 billion and NPATA — net profit after tax before acquired-intangible amortisation and certain one-off items — of about US$3.1 billion, both on a constant-currency basis, which strips out exchange-rate moves. Interim CEO Gordon Naylor said “growth initiatives are working,” but the financial benefits would take longer to show. The company also pointed to revenue hits from U.S. immunoglobulin channel inventory, China albumin, HEMGENIX and iron competition, and said about US$5 billion in pre-tax impairments remained subject to further review, audit and board approval.
CSL’s main businesses span CSL Behring, CSL Seqirus and CSL Vifor, covering plasma products, gene therapies, influenza vaccines, pandemic services, iron deficiency and nephrology. That mix keeps the market focused on plasma execution, not just vaccine demand.
Broker views remain split. TipRanks data showed UBS analyst David Low reiterated a buy rating on CSL on June 9 while cutting the target to A$158 from A$175; other recent calls ranged from hold ratings at Macquarie, Citi, Jefferies and Bell Potter to buy ratings from Morgan Stanley and Morgans.
Morgans analyst Derek Jellinek framed the bull case more bluntly last month, writing that “credibility has clearly been damaged” and visibility was weak, but that he did not believe CSL’s core plasma franchise was “structurally broken.” Morgans kept a buy rating while cutting its target to A$147.59. Stockhead
The risk is that Tuesday’s rise proves to be only a trading bounce. If U.S. immunoglobulin inventory normalisation takes longer, China albumin pricing weakens further, or iron competition bites harder than CSL now assumes, the market may again test whether the May reset was deep enough.
For now, investors have bought CSL back toward A$100. The next hard test is not Tuesday’s close; it is whether the company can show, at full-year results, that the clean-up is turning into earnings traction.
